Clinical Scorecard: The Impact of Natural Testosterone Levels and Supplementation on Cardiovascular Health in Men
At a Glance
Category
Detail
Condition
Low endogenous testosterone and testosterone supplementation effects on cardiovascular health
Key Mechanisms
Testosterone regulates sexual development, body composition, and bone mass; low levels associate with aging, obesity, and comorbidities influencing cardiovascular risk
Target Population
Middle-aged to older men, especially those with low testosterone, dysglycemia, or cardiovascular risk factors
Care Setting
Primary care and specialized endocrinology or cardiology clinics managing aging men with cardiovascular risk or androgen deficiency
Key Highlights
Lower endogenous testosterone concentrations are found in men with preexisting cardiovascular disease, influenced strongly by age, BMI, and comorbidities.
Large cohort studies show nonlinear associations between low testosterone (<7.4 nmol/L) and increased all-cause and cardiovascular mortality.
Randomized trials (T4DM and TRAVERSE) indicate testosterone treatment reduces type 2 diabetes risk without increasing major adverse cardiovascular events over ~3 years.
Guideline-Based Recommendations
Diagnosis
Evaluate men with hypothalamic, pituitary, or testicular disease for androgen deficiency with full medical assessment.
Measure total and free testosterone using mass spectrometry when possible for accurate assessment.
Consider age, BMI, and comorbidities when interpreting testosterone levels.
Management
Testosterone treatment is effective for men with clinical androgen deficiency due to hypothalamic, pituitary, or testicular disease.
In men without such diseases, avoid testosterone misuse; focus on lifestyle interventions to improve cardiometabolic health.
Testosterone therapy may reduce type 2 diabetes risk in men with dysglycemia when combined with lifestyle changes.
Monitoring & Follow-up
Monitor cardiovascular outcomes and metabolic parameters during testosterone therapy, especially in men with existing cardiovascular risk.
Long-term cardiovascular safety requires further study; ongoing surveillance is recommended.
Risks
No increased risk of major adverse cardiovascular events observed in trials up to 3 years.
Potential risks related to androgen misuse and abuse in men without clinical deficiency.
Uncertain long-term cardiovascular safety necessitates cautious use and further research.
Patient & Prescribing Data
Middle-aged to older men with low testosterone and/or dysglycemia, including those with cardiovascular risk factors
Testosterone treatment reduces progression to type 2 diabetes in men with dysglycemia and does not increase major cardiovascular events over 3 years; benefits and risks should be balanced with lifestyle interventions.
Clinical Best Practices
Use mass spectrometry for accurate testosterone measurement when possible.
Assess and address modifiable cardiovascular risk factors alongside testosterone evaluation.
Reserve testosterone therapy for men with confirmed androgen deficiency due to hypothalamic, pituitary, or testicular disease.
Avoid testosterone misuse in men without clinical deficiency; promote healthy lifestyle behaviors.
Monitor patients on testosterone therapy for cardiovascular and metabolic outcomes regularly.
